The COVID-19 pandemic highlighted the need for fast-produced and adaptable vaccines that could be equally distributed around the world. Developing an efficient mRNA vaccine that is effective, thermostable, and has fewer side effects strongly depends on lipid nanoparticles (LNPs) which preserve and deliver mRNA to cells. Lipid nanoparticles appear to be the sole solution to global health issues, and that is why well-known biopharma companies and startups are currently focusing exactly on this.
It might sound easy, but it is not. COVID-19 mRNA vaccines widely used worldwide, such as Comirnaty by Pfizer/BioNTech and Spikevax by Moderna, are proven effective and safe. There are, however, some downsides to current mRNA technologies.
Another issue with today’s COVID-19 mRNA vaccines are the common side effects such as inflammation, fever, and aches. These side effects are caused by lipids which are not fully biodegradable, therefore not disintegrating completely in the body after their work is done. The other challenge of the LNP development is the constant need to adapt to new variants while entrapping bigger payloads to be more efficient.
What can be done to advance LNP technology and the future of mRNA vaccines? As a matter of fact, a lot of scientists are already working on this innovation.
AexeRNA Therapeutics, co-founded by Dr. Drew Weissman, whose research paved the way for the mRNA vaccines, has a proprietary ionizable lipid library. This gives the ability to quickly select the optimal lipids for immunization or therapeutic application. It means that the technology can become more rapidly adjustable to the new variants or applied to other diseases.
The company’s research exemplifies some promising results in mRNA delivery efficiency with controlled distribution to various organs. AexeRNA’s LNP platform is also addressing side effects by lowering toxicity of the system. Their research is dealing with logistics issues by making the vaccine easier to store and transport.
Dr. Pieter Cullis, another world-renowned scientist, has been working on LNP technology for decades. He co-founded and served on the board of more than ten companies, one of which is NanoVation Therapeutics. This company focuses on personalized gene therapeutics. Their pre-clinical studies are focused on the efficacy and biodistribution of LNPs making their research valuable for developing mRNA vaccines.
The other company co-founded by Cullis and led by Dr. Thomas Madden, Acuitas Therapeutics, has an agreement with Pfizer/BioNTech to use its proprietary lipid nanoparticle technology in the development of COVID-19 vaccines. Moreover, the same LNP components can be used in different mRNA vaccines, simplifying their creation for future variants and other diseases.
Last but not least is the revolutionary biopharma startup NeoVac. Using novel lipid nanoparticle technology developed by the company’s co-founder Professor Dan Peer at his Lab at Tel Aviv University, the company aims to overcome existing challenges with the LNPs technology. NeoVac’s in-vivo studies showed fewer side effects due to the fully biodegradable lipids that compose the LNPs. NeoVac’s LNPs have no effect on the liver in fatty liver disease as compared to significant damage by some other vaccines. In addition, their delivery system entraps triple the currently available RNA load and can address multiple variants with multiple payloads simultaneously. This results in higher effectiveness without increasing the dose.
mRNA has proven effective during pandemics and is promising in preventing and treating many other diseases, including cancer. The development of LNPs is crucial for the success of mRNA technologies. The future of global health is in the hands of biopharma companies that are on their way to creating mRNA vaccines with a lower cost of storage and transportation, fewer adverse effects, and faster response to the new variants.
Daegu Gyeongbuk Institute of Science & Technology (DGIST, President Yang Kook) Professor Hongsoo Choi’s team of the Department of Robotics and Mechatronics Engineering collaborated with Professor Sung-Won Kim’s team at Seoul St. Mary’s Hospital, [...]
Tiny nets woven from DNA strands can ensnare the spike protein of the virus that causes COVID-19, lighting up the virus for a fast-yet-sensitive diagnostic test—and also impeding the virus from infecting cells, opening [...]
Roughly two decades ago, a strategy called optogenetics emerged to control brain activity with lasers. It uses viruses to insert genes into cells that make them sensitive to light. Optogenetics has revolutionized neuroscience by giving researchers [...]
Shigella bacteria, which causes Shigellosis, is the primary cause of bacterial diarrhea and diarrheal death among juveniles under five years of age. Because of the antibiotic resistance of Shigella strains, no commercial vaccines are available to date. [...]
Scientists have built microscopic robots equipped with electronic “brains” that are capable of walking autonomously. A team from Cornell University in the US developed the solar-powered bots as part of research into a new generation of [...]
Blood samples from patients with long COVID who are still suffering from fatigue and shortness of breath after a year show signs of autoimmune disease, according to a study published today (Thursday) [...]
High-grade serous ovarian cancer (HGSOC) is among the deadliest human cancers and its prognosis remains extremely poor. An article published in Advanced Science explored the self-therapeutic properties of gold nanoparticles to identify a molecular axis that [...]
Antimicrobial peptides (AMPs) have a broad spectrum of antimicrobial activity and lyse microbial cells by interaction with biomembranes, offering great potential in designing new therapeutics. The antimicrobial resistance (AMR) caused due to overuse of [...]
Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a [...]
Hyperspectral microscopy is an advanced visualization technique that combines hyperspectral imaging with state-of-the-art optics and computer software to enable rapid identification of nanomaterials. Since hyperspectral datacubes are large, their acquisition is complicated and time-consuming. [...]
Malignant brain tumors are cancerous growth in the brain with the possibility of spreading to other parts of the central nervous system (CNS). Brain tumors are highly invasive and have devastating consequences, poor prognosis, [...]
An ultrathin invention could make future computing, sensing and encryption technologies remarkably smaller and more powerful by helping scientists control a strange but useful phenomenon of quantum mechanics, according to new research recently published [...]
Methacrylate-based materials are often used in bone cement and dental resins. However, they have high failure rates as they undergo damage within ten years, impacting the quality of patient’s life and increasing healthcare costs. [...]
Early diagnosis of an infectious viral disease can help the patients and health care professionals monitor the outbreaks accurately and provide treatment at the early stage of a disease, avoiding any detrimental consequences. The [...]
Researchers at Duke University have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell. Loaded with light scattering dyes called Raman reporters commonly used [...]
A household microwave oven modified by a Cornell Engineering professor is helping to cook up the next generation of cellphones, computers and other electronics after the invention was shown to overcome a major challenge [...]